DeepMed Research

BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986278
Drug: Placebo
Drug: Sildenafil

First Posted Date: 2023-01-13

Last Posted Date: 2023-08-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 61

Registration Number: NCT05684289

Locations: 🇺🇸
Syneos Health Clinical Research Services, Llc, Miami, Florida, United States
🇺🇸
Altasciences Clinical Los Angeles, Inc, Cypress, California, United States

A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid Tumors

Phase 1

Withdrawn

Conditions: Advanced Solid Tumors

Interventions: Drug: [14C]CC-90010
Drug: CC-90010

First Posted Date: 2023-01-10

Last Posted Date: 2024-04-17

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT05678283

Locations: 🇪🇸
Local Institution - 0002, Madrid, M, Spain

A Study to Assess Real-World Patient-Reported Outcomes With Fedratinib for Myelofibrosis Post-Ruxolitinib

Completed

Conditions: Myelofibrosis

First Posted Date: 2022-12-27

Last Posted Date: 2025-04-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 150

Registration Number: NCT05665192

Locations: 🇺🇸
Cardinal Health Specialty Solutions, Dublin, Ohio, United States

A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia

Phase 2

Recruiting

Conditions: Anemia

Interventions: Biological: Luspatercept
Drug: Placebo

First Posted Date: 2022-12-27

Last Posted Date: 2025-05-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 249

Registration Number: NCT05664737

Locations: 🇨🇦
Local Institution - 0008, Halifax, Nova Scotia, Canada
🇨🇳
The First People's Hospital of Foshan, Foshan, Guangdong, China
🇨🇳
Local Institution - 0029, Guangzhou, Guangdong, China

and more 33 locations

A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Recruiting

Conditions: Multiple Sclerosis, Relapsing-Remitting

First Posted Date: 2022-12-21

Last Posted Date: 2024-01-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 180

Registration Number: NCT05658601

Locations: 🇮🇹
Neuromed Istituto Neurologico Mediterraneo, Isernia, Italy

A Study to Assess the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Mavacamten Capsule 1
Drug: Mavacamten Capsule 2
Drug: Mavacamten Capsule 3

First Posted Date: 2022-12-20

Last Posted Date: 2023-10-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 95

Registration Number: NCT05658146

Locations: 🇺🇸
Local Institution - 0001, Anaheim, California, United States
🇺🇸
Local Institution - 0002, Miami, Florida, United States
🇺🇸
Local Institution - 0003, Springfield, Missouri, United States

A Study to Evaluate Efficacy and Long-term Safety of Oral Ozanimod in Chinese Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Phase 3

Terminated

Conditions: Ulcerative Colitis

Interventions: Drug: Placebo
Drug: Ozanimod

First Posted Date: 2022-12-09

Last Posted Date: 2025-03-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 131

Registration Number: NCT05644665

Locations: 🇨🇳
Local Institution - 0012, Hefei, Anhui, China
🇨🇳
Local Institution - 0013, Wuhu, Anhui, China
🇨🇳
Local Institution - 0052, Beijing, Beijing, China

and more 48 locations

A Study to Evaluate the Safety and Tolerability of Cendakimab in Chinese Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Placebo
Drug: Cendakimab

First Posted Date: 2022-12-06

Last Posted Date: 2023-08-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 25

Registration Number: NCT05638282

Locations: 🇨🇳
Local Institution - 0001, Guangzhou, Guangdong, China

A Study to Assess Deucravacitinib Post-marketing Surveillance in Participants With Psoriasis in Japan

Recruiting

Conditions: Psoriasis

First Posted Date: 2022-12-01

Last Posted Date: 2024-06-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 300

Registration Number: NCT05633264

Locations: 🇯🇵
EP Pharmaline, Tosima-ku, Tokyo, Japan

A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: BMS-986360
Drug: Docetaxel
Drug: Nivolumab
Drug: Capecitabine

First Posted Date: 2022-11-22

Last Posted Date: 2025-05-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 220

Registration Number: NCT05625412

Locations: 🇺🇸
Local Institution - 0046, West Valley City, Utah, United States
🇺🇸
Local Institution - 0029, Los Angeles, California, United States
🇺🇸
Local Institution - 0051, Los Angeles, California, United States

and more 32 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy